IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
March 19 2024 - 8:30AM
via IBN – IBN, a multifaceted communications organization engaged
in connecting public companies with the investment community, today
announces that Rob Etherington, President, Director and CEO of late
clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN),
recently appeared on First in Human, a biotech-focused podcast
featuring interviews with industry leaders and investors to learn
about their journeys to in-human clinical trials.
The podcast, hosted by Vial EVP, Rich McCormick, is available
for on-demand listening on First in Human by Vial.
During the interview, Etherington highlighted information about
Clene’s work in the field of nanotechnology.
“For decades…the idea of a therapeutic elemental metal having
some medicinal efficacy has been well understood. We at Clene had
the idea to combine this with the mechanism of a nanotherapeutic,
providing, at the atomic level, the ability to drive energy into
the failing mitochondria that powers your and my brain. We had the
idea to do that with a catalytically active nanotherapeutic
suspension, which the patients drink daily.”
“We first completed some translational medicine work, whereby we
were able to show that our drug taken orally got into the stomach
then into the bloodstream and then across the blood brain barrier
to drive the key bio energetic metabolites that you and I rely upon
for energy… we were able to reverse the clock potentially by
decades, in terms of key bioenergetic metabolites. We then
proceeded into two amyotrophic lateral sclerosis (ALS) studies and
one multiple sclerosis study, all of which have concluded in the
past 18 months. These studies have shown the ability (of CNM-Au8®)
to improve function, which can be translated as how to improve the
way patients move and walk and talk and eat and chew and
breathe.”
Throughout the interview, Etherington continued to detail
Clene’s efforts in nanotechnology, discussing how this approach
differentiates the company’s pipeline from traditional treatment
options.
Learn more by listening to the full episode on First in Human by
Vial.
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 17+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Clene (NASDAQ:CLNN)
Historical Stock Chart
From Oct 2024 to Oct 2024
Clene (NASDAQ:CLNN)
Historical Stock Chart
From Oct 2023 to Oct 2024